Good morning, ladies and gentlemen, and welcome to the 2026 Annual Meeting of Stockholders of Twist Bioscience Corporation. My name is Robert Chess, and I am the Lead Independent Director of the board of directors and will act as chairman of the 2026 annual meeting of stockholders of Twist Bioscience Corporation. I'm very happy to welcome each of you, and the company is pleased to have each of you in attendance via the web portal. Before I call the meeting to order, I would like to introduce the other members of the board and the business team who are with us today. The other members of the board in attendance at this meeting are Nelson Chan, Keith Crandell, Trynka Shineman Blake, Jan Johannessen, Robert Ragusa, Melissa Starovasnik, Emily Leproust.
The following officers of the company are also with us today: Emily Leproust, Patrick Finn, Adam Laponis, Paula Green, Dennis Cho, Angela Bitting. Dennis Cho will act as secretary for this meeting. In addition, I would like to introduce Ray Manahan, who is in attendance as a representative. Ernst & Young LLP are independent registered public accounting firm. The meeting will now officially come to order. We will proceed with the formal business of the meeting as set forth in the notice of annual meeting and proxy materials mailed to stockholders who held shares of our common stock as of the record date for this meeting. After the formal part of the meeting, Emily Leproust, the CEO of the company, will give validated stockholders an opportunity to ask questions subject to the rules and procedures for the meeting, which are posted on the web portal.
Though we may not be able to answer every question, we will do our best to provide a response to as many as possible and will address any unanswered questions on our corporate website shortly after the meeting. Out of consideration for others, please limit yourself to one question. Please note that no one attending via the webcast or telephone is permitted to use any audio recording device. Will the secretary please report at this time with respect to the Record Date and the mailing of the Notice of Annual Meeting?
December 26, 2025, was set by resolutions of the Board of Directors as the Record Date for today's Annual Meeting. We also have affidavits attesting to the fact that the Notice of Annual Meeting, the Proxy Statement, and the company's 2025 Annual Report to stockholders were mailed to all stockholders of record as of the Record Date beginning on or about January 6, 2026.
At this time, I'd like to introduce Kathy Blackwell. The board has appointed Kathy Blackwell as a representative of Broadridge to act as the Inspector of Election at this meeting. She has taken and subscribed the customary oath of office to execute the duties of Inspector of Election with strict impartiality. We will file this oath with the records of the meeting. The function of the Inspector of Election is to decide upon the qualifications of voters, accept their votes, and, when balloting on all matters is completed, to tally the final votes. Will the Inspector of Election please report at this time with respect to the existence of a quorum?
Proxies have been received for 56,260,506 shares of the outstanding shares of Twist Bioscience Corporation common stock. Collectively, the votes for which these proxies were received represent approximately 91.81% of the total number of votes that may be cast by the outstanding shares. This constitutes a quorum for the meeting today.
If any stockholder is planning on voting at this meeting, he or she may do so by clicking on the voting button on the web portal and following the voting instructions. If you have already submitted a proxy and do not wish to change your vote, you do not need to take any further action. Your shares will be voted as you have directed. The time is 7:04 A.M. Pacific Time, and the polls are now open for voting on all matters to be presented.
We will now proceed with the formal business of the meeting. There are three proposals to be considered by the stockholders at this meeting, which I will summarize and which are more fully described in the proxy statement for this meeting. The first item of business is the election of three directors to serve until the 2029 annual meeting of stockholders and until their successors are elected and qualified, or until their earlier resignation or removal. The nominees for directors are Keith Crandell, Jan Johannessen, Trynka Shineman Blake. The board of directors recommends a vote for all three director nominees. The second item of business is the approval, on a non-binding and advisory basis, of a resolution approving executive compensation as described in detail in the proxy statement delivered to stockholders in connection with this meeting. The board of directors recommends a vote for this proposal.
The third and final item of business is the ratification of the selection by the audit committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the company for the fiscal year 2026. The Board of Directors recommends a vote for this proposal. If any stockholder has a question regarding any of the proposals before the polls close, please submit your question through the Web Portal.
Polls are now closed for voting. I ask Kathy Blackwell, as our designated inspector of election for this meeting, to tabulate and certify the results.
May we have the results of the voting?
The preliminary report of the inspector of election covering the proposals presented at this meeting is as follows. The nominees for election to the board, Keith Crandell, Jan Johannessen, and Trynka Shineman Blake, have been duly elected. The resolution approving executive compensation has been approved on a non-binding advisory basis. The proposal to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the company for 2026 has been approved. A full tally of the votes will be published in the current report on Form 8-K, which will be filed with the Securities and Exchange Commission within four business days.
The 2026 annual meeting of stockholders is now adjourned. I want to thank all of you for attending today's meeting and for the interest you have shown in the affairs of our company. Dr. Leproust will now entertain questions from stockholders subject to the rules of procedure for this meeting. You may submit questions through the web portal by typing your question into the Ask a Question box and clicking Submit to submit your question. Again, we ask that stockholders limit their question to one per stockholder. Seeing no questions, that is all the time we have for today. Thank you for attending the meeting today.
Ladies and gentlemen, this concludes the meeting. You may now disconnect.